Core Laboratories (CLB) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
30 Jul, 2026Executive summary
Q2 2026 revenue was $124.6 million, up 2% sequentially but down 4% year-over-year, with continued execution of a technology-focused strategy despite significant geopolitical disruptions in the Middle East and Russia/Ukraine, leading to project delays and logistical challenges, especially in Reservoir Description.
Production Enhancement segment showed resilience with improved energetic product sales and increased operator adoption of proprietary technologies in both U.S. and international markets.
Maintained commitment to shareholder returns through dividends and share repurchases, marking the seventh consecutive quarter of buybacks, with 214,712 shares repurchased for $2.7 million and a quarterly dividend of $0.01 per share.
Focused on maximizing free cash flow, return on invested capital, and returning excess cash to shareholders.
Free cash flow for the quarter was $3.1 million.
Financial highlights
Q2 2026 revenue was $124.6 million, up 2% sequentially but down 4% year-over-year.
Service revenue was $94.3 million, flat sequentially and down 2% year-over-year; product sales were $30.3 million, up 10% sequentially but down 11% year-over-year.
EBIT ex items was $9.4 million (8% margin), up from $6.6 million last quarter; net income ex items was $5.1 million, up from $2.7 million last quarter but down from $8.8 million a year ago; net income GAAP was $5.8 million; diluted EPS was $0.13; adjusted EPS was $0.11, up from $0.06 last quarter but down from $0.19 last year.
Free cash flow for the quarter was $3.1 million; cash from operations was $7.8 million.
Net debt at $93.6 million as of June 30, 2026; leverage ratio at 1.3.
Outlook and guidance
Q3 2026 revenue projected at $128.5–$135.5 million, with operating income of $10.5–$15 million and operating margins around 10%; EPS for Q3 expected to range from $0.12–$0.20.
Reservoir Description Q3 revenue expected at $81–$84 million; Production Enhancement at $47.5–$51.5 million.
Sequential revenue growth expected, driven by improvements in Africa, Brazil, Asia-Pacific, and parts of Europe, with only marginal improvement anticipated in the Middle East and modest improvement in U.S. land completion activity.
Guidance excludes FX gains/losses and assumes a 25% tax rate.
Long-term fundamentals remain strong, with global demand growth projected to rebound in 2027.
Latest events from Core Laboratories
- Q2 2024 revenue up, margins and free cash flow improved, debt reduced, international growth strong.CLB
Q2 20248 Jul 2026 - 2025 meeting covers director elections, auditor ratification, and performance-based executive pay.CLB
Proxy filing18 May 2026 - Votes will address director elections, auditor ratification, and executive compensation approval.CLB
Proxy filing18 May 2026 - Sequential revenue and margin growth, 21% net income rise, and share buybacks marked Q3 2025.CLB
Q3 202518 May 2026 - Proxy covers director elections, auditor ratification, and executive pay, with strong ESG focus.CLB
Proxy filing18 May 2026 - Q1 2026 revenue and margins fell on geopolitical and weather disruptions; modest Q2 rebound expected.CLB
Q1 202618 May 2026 - Votes on director re-election, auditor ratification, and executive pay set for May 2026.CLB
Proxy filing18 May 2026 - Q4 revenue up 7% year-over-year; Q1 2026 guidance: $124–$130M revenue, $0.11–$0.15 EPS.CLB
Q4 20255 Feb 2026 - Q3 2024 delivered 7% revenue growth, margin gains, and record-low leverage on strong international demand.CLB
Q3 202418 Jan 2026